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Abstract 
 
Phospholipids biosynthesis, particularly phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) plays a major role in the survival of T. brucei. Of great 
importance is the fact that, as opposed to other parasitic organisms, trypanosomes 
synthesize phospholipids de novo. Although the pathways for phospholipids biosynthesis 
have not been very well characterized, recent data have helped to better understand how 
trypanosomes are able to assemble phospholipids. Previous work in our lab has shown 
that a protein, termed TbLpn, is a phosphatidic acid phosphatase potentially involved in 
phospholipid biosynthesis in T. brucei. In addition, TbLpn contains methylated arginine 
residues and interacts with T. brucei major Protein Arginine Methyltransferases, 
TbPRMT7. The major focus of my project is to identify the effect of TbLpn methylation 
by TbPRMT7 on its enzymatic activity and cellular localization.  
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Introduction 
 Trypansoma brucei is a single celled, parasitic, protozoan organism that is 
responsible for causing “African trypanosomiasis,” or more commonly known as, 
“African sleeping sickness.” African sleeping sickness is transmitted when a person is 
bitten by a tsetse fly. These flies are native to Sub-Saharan Africa, and harbor T. brucei, 
and inject it into their human or animal target (1). This illness initially causes fever, 
headache, muscle pain, joint pain, and enlarged lymph nodes in the initial stages of the 
sleeping sickness, and eventually experience severe mental deterioration, paralysis, 
disturbances in the sleep cycle, and death within a few months of infection (2).  
Cellular Structure of Trypanosoma brucei 
The cellular make-up of T. brucei is very unique.  This protozoan contains a 
kinetoplast, a compact disc that houses mitochondrial DNA, to store its genetic material, 
and a singular flagellum for locomotion (1).  In order to maintain its shape, T. brucei uses 
a corset-like cytoskeleton made of microtubules, and is aptly named the “microtubule-
corset.” This protects the organism from damage and may possibly increase its chances of 
survival in adverse chemical or physical conditions (1).  The flagellum gains its shape by 
the interactions between the flagellar axoneme, paraflagellar rod, and the flagellum 
attachment zone. The flagellar axoneme consists of several tubules in a circular formation 
spanning the entire length of the flagellum, giving it a long, cylindrical structure. The 
paraflagellar rod’s precise function is still unknown, but it spans the majority of the 
flagellar length, and is important in maintaining the movement of the flagellum. Four 
microtubules and a specialized filament compose the flagellum attachment zone. This 
structure is located just beneath the flagellum on the microtubule corset.  The flagellum 
exits the Trypanosome through the flagellar pocket, which allows for free movement of 
the flagellum (1). 
T. brucei Life Cycle 
 Understanding the life cycle of Trypanosoma brucei helps researchers to 
understand the complex relationship between T. brucei and its vector host, the tsetse fly. 
After initial human infection caused by a bite from an infected tsetse fly, metacyclic 
trypomastigotes are inserted into the human blood stream (3) from the salivary glands of 
the tsetse fly (1). These metacyclic trypomastigotes become bloodstream trypomastigotes 
and can then be carried to other areas within the human body (3).  Asexual reproduction 
occurs through binary fission once the bloodstream trypomastigotes enter body fluids 
including the blood, lymph, and spinal fluid (3).  
 If the infected mammalian host is bitten by an uninfected tsetse fly, this fly will 
become a carrier of T. brucei. Once the fly ingests infected blood, the parasite will infect 
the host fly’s mid-gut. Here, they will transform into procyclic trypomastigotes (3). In the 
mid-gut, this type of trypomastigotes will divide, again, by means of binary fission. Once 
the procyclic trypomastigotes leave the gut, they will evolve into epimastigotes. In this 
stage, the parasite may enter the tsetse fly salivary glands and transform into metacyclic 
trypomastigotes.  Now, the parasite may exit the tsetse fly vector and enter a new 
mammalian host, starting the life cycle over again, as shown in Figure 1 (3).  
Once the host is infected by T. brucei, the host will begin the development of 
African Trypanosomiasis, or African sleeping sickness. This illness develops in two 
distinct stages, defined by location of T. brucei. In stage I, the parasite can be found in 
general circulation throughout the body, in locations such as the blood and lymph. During 
this stage, symptoms include: fever, headache, muscle pain, joint pain, swollen lymph 
nodes, weight loss, and swelling or itchiness of the insect bite, or a “chancre (2).”  This 
stage can last anywhere from one to two weeks, to several years. The completion of stage 
I is marked by the entrance of T. brucei into the cerebrospinal fluid. Stage II begets more 
complicated and dangerous symptoms than stage I. Stage II can cause severe mental 
deterioration, personality changes, difficulties in staying awake during the day, inability 
to sleep through the night, paralysis, difficulties in balancing or walking, hormonal 
imbalances, coma, and, eventually, death (2). Diagnosis of African Trypanosomiasis can 
be made through microscopic analysis of the lymph node aspirate. To determine whether 
the illness had progressed to stage II, the cerebrospinal fluid must be examined (4).  
 
 
Figure 1. The life cycle of Trypanosoma brucei (3) 
Recorded Epidemics of Human African Trypanosomiasis 
 There are two different species of Trypanosoma brucei that can cause African 
sleeping sickness in humans (5). Trypanosoma brucei rhodesiense is most commonly 
found in Tanzania, Uganda, Malawi, and Zambia.  This strain of T. brucei primarily 
affects cattle, but can affect hunters who visit East Africa (5). Trypanosoma brucei 
gambiense most commonly affects the Democratic Republic of Congo, Angola, Sudan, 
Central African Republic, Chad, and northern Uganda (5).  This strain is the most 
common cause of Human African Trypanosomiasis (HAT) in human subjects, causing 
7,000 to 10,000 infections each year (5).  Most commonly, disease transmission occurs 
through tsetse fly bite, but can be transmitted through mechanisms of blood contact 
including shared needles and blood transfusions, and can be transmitted sexually, or from 
pregnant mother to unborn fetus (5).  
 During the years of 1889-1896, Africa experienced its first recorded African 
sleeping sickness epidemic. As a result of increased colonization of African countries, 
death of 90% of the livestock population, and a series of natural disasters, the tsetse fly 
began targeting humans as their primary food source.  The World Health Organization 
estimates that from areas along the Congo River to Lake Victoria, 500,000 people died 
(6). In 1901, an epidemic occurred in Uganda, wiping out an estimated 200,000 people in 
four years (7). African sleeping sickness outbreaks also occurred in Tanzania and Sudan 
from 1904-1905, Northern Rhodesia and Nyasaland in 1908 (7).  As a result of these 
epidemics, imperialistic countries sent scientists to Africa to study pathogen causing 
“nagana,” the livestock variation of African Trypanosomiasis. David Bruce discovered 
this pathogen, and T. brucei was named for him (7).  These scientific missions trips 
started the initial research into treatment for African sleeping sickness, and generated 
interest in understanding the trypanosome itself. 
 Uganda experienced a prolonged outbreak of African Trypanosomiasis from 1900 
to 1920, and again from 1976-1989 (8). The most recent outbreak was linked to 
degradation in sociopolitical stability, and this epidemic’s downfall was linked with a 
return to stability and re-establishment of public health awareness measures (8).  
 Because of the preventative measures some African governments have taken 
against African sleeping sickness, the incidence of this illness had decreased significantly 
in once heavily affected areas (9).  For the first time in over 50 years, the number of 
reported cases per year has dropped below 10,000 (9). This does not include unreported 
cases, but the World Health Organization estimates that the overall incidence of this 
illness has still dropped based on the sample of the populations they have tested. T. b. 
gambiense is responsible for 97% of the African Trypanosomiasis cases that have been 
recorded. It typically affects areas of West Africa, Central Africa, and, most notably, the 
Democratic Republic of the Congo. West Africa and Central Africa both showed low to 
very low prevalence and transmission of T. b. gambiense from 2001 to 2010.  The 
Democratic Republic of the Congo produces over 80% of the total Human African 
Trypanosomiasis cases (9) and has some areas of very low prevalence of HAT, and some 
areas that still exhibit very high prevalence of HAT. The areas that exhibit the most cases 
of African sleeping sickness are the areas of African countries that have the greatest 
amount of poverty, least advanced healthcare, lowest health priority, social instability, 
and the greatest geographical isolation (10).  There is a high concentration of these areas 
in the Democratic Republic of the Congo, which has lead to their higher incidence of 
HAT in certain areas.  
 Trypanosoma brucei rhodesiense accounts for less that 3% of all Human 
African Trypanosomiasis (9). This strain usually only affects areas of East Africa, and 
mainly affects cattle and wild animals.  While there is very low risk of human 
transmission of this virus, it cannot be disregarded when studying the epidemiology of 
HAT (9).  
 
Current Treatment Methods for HAT 
There are few affective treatments currently in use to treat both forms of HAT. The blood 
stream and lymph stage, or “Hemolymphatic” stage, of T. b. gambiense can be treated 
using Pentamidine (Figure 2). This drug should be administered through an intravenous 
infusion (IV) or intramuscular injection (IM).  Four milligrams of Pentamidine should be 
administered per kilogram the patient weight, per day for seven to ten days (11). If the 
medication is administered using an IV, the IV should be given over two hours (11). Side 
effects of this medication include pain at injection site, low blood sugar, diarrhea, nausea, 
and vomiting (11).   
 
Figure 2. Pentamidine 
Once this parasite crosses into the central nervous system, Eflornithine (Figure 
3) becomes the most affective treatment. This drug should be administered 4 times 
each day for 14 days using an IV. 400 milligrams should be administered per kilogram 
the patient weights each day.  This treatment can cause bone marrow suppression, 
gastrointestinal abnormalities, and seizures (11).  
 
Figure 3. Eflornithine 
 
Two different drugs are used to treat the two different stages of T. b. 
rhodesiense. Suramin (Figure 4) is used to fight the hemolymphatic stage.  One gram 
of Suramin should be administered to adults affected by the East African form on 
HAT over a 21 day period, on days 1,3,7,14, and 21.  For children who contract this 
form of HAT, the dosage is decreased to 20 milligrams per kilogram, on the same 
dosage schedule. Side effects include a rash, nephrotoxicity, and peripheral 
neuropathy (11). These side effects are common, but are usually mild and reversible 
(11).   
 
 
Figure 4. Suramin  
 
Melarsoprol (Figure 5) is an arsenic based drug, and is the only effective 
treatment for stage two T. b. rhodesiense.  This treatment can cause encephalitis in 5-
10% of patients, and as a result produces a 50% fatality rate in patients who 
experience this side effect.  In some patients, the use of corticosteroids can be 
effective in reducing the risk of encephalitis (11). Melarsoprol can also cause skin 
reactions, gastrointestinal irritation, peripheral neuropathy, and phlebitis at the site of 
intravenous injection (11).  Because this drug has so many devastating side effects, the 
dosage schedule is very complicated. On the first day of treatment, the patient will 
receive two 3.6 milligram per kilogram doses via an IV. This dosage will be repeated 
for the first three days of treatment. After seven days, another 3.6 milligram per 
kilogram per day dose will be administered every day for three days. Then, after 
another seven days, the patient must receive a final 3.6-milligram per kilogram dose of 
Melarsoprol (11).  
 
Figure 5. Melarsoprol 
 
 
Antigenic Variation of T. brucei 
A unique immune system evasion adaptation that Trypanosoma brucei has 
developed is termed “antigenic variation.”  This method involves a switch of VSGs, 
or, Variant Surface Glycoproteins. These proteins coat the cell in a protective layer 
and allow for antigenic variation to occur (12).  The region where VSGs exist on the 
surface of the cell is only about 15 nanometers thick and are both synthesized and 
cleaved in the endoplasmic reticulum (13). VSGs are secured to the surface of the 
trypanosome by glycosylphosphatidylinositol (GPI), which is also synthesized in the 
endoplasmic reticulum (14).  
 Once the host immune system recognizes the trypanosome; it is very effective at 
eliminating 99% of the parasites present.  Approximately 1% of the remaining cells will 
contain a different type of VSG. The remaining 1% of the cells will reproduce and will 
contain a different, but singular, type of glycoprotein on the cell membrane.  The host 
immune system will have built a defense against this new strain on T. brucei, so it is able 
to continue the progression of African Trypanosomiasis (14). Expression of VSG occurs 
at polycistronic telomere expression sites.  Each VSG is expressed in a monoallelic 
fashion, meaning that only one of approximately 15 VSG expression sites is transcribed 
at a time (15). All other telomeric expression sites are silenced when one singular site is 
being transcribed.  It has been estimated that 20-30% of the trypanosome genome is 
devoted to storing over 2,000 different VSG genes (15). This strategy of randomly 
varying surface proteins makes it impossible to create a vaccine against African 
Trypanosomiasis. 
Arginine Methylation 
Arginine methylation is an important posttranscriptional modification made to 
certain proteins, resulting in an extra methyl carbon group on the N-terminus of certain 
proteins.  This adjustment aids in several essential processes, including cell signaling, 
RNA processing, DNA repair, and chromatin remodeling (16). There are four general 
types of PRMTs that have been identified thus far.  These types are characterized by the 
amount of modification performed on an individual arginine residue from a methyl 
donor, usually S-adenosylmethionine, or “AdoMet,” on a terminal side (17). If the 
enzyme only catalyzes the addition of one methyl group to the terminal nitrogen side of 
an arginine reside, the enzyme is classified as type III.  If the PRMT may transfer a 
second methyl carbon group to the same terminal nitrogen, resulting in the formation of 
omega NG -NG -asymmetric dimethylarginine (ADMA), the enzyme is classified as type 
I.  If a third methyl group is added by an enzyme to the nitrogen adjacent to the already 
dimethylated arginine residue, leading to the production of omega NG -NG -symmetric 
dimethylarginine (SDMA), the enzyme is classified as type II.  While type IV PRMTs 
have only been found in certain yeasts, they are still relevant.  Type IV PRMTs have the 
ability to transfer a single methyl group to an internal nitrogen on an arginine residue 
(17).  
In Trypanosoma brucei, there are five types of protein arginine methyltransferases 
(PRMT). TbPRMT1, TbPRMT3, and TbPRMT6 are type I PRMTs, while TbPRMT5 is a 
type II enzyme. As for TbPRMT7, it is classified as a type III PRMT as it has been 
shown to catalyze the addition of only one methyl group.. TbPRMT1 is responsible for 
the vast majority of AMDA formation in vivo, similar to what is observed in mammalian 
cells (17). TbPRMT3 has not been associated with a specific function in T. brucei yet.  In 
humans, PRMT3 facilitates ribosome assembly (17).  Conversely, the enzyme TbPRMT5 
has several known functions. It is able to methylate DEAD-box RNA helicase in vitro, 
has a very broad substrate range, and may affect RNA metabolism (17). TbPRMT6 lacks 
to ability to methylate certain targets however, it may have the ability to modify 
trypanosomal histones (17).  TbPRMT7 is where I focused my research. This enzyme has 
been found to be 30 times more active than its human counterpart based on methyl 
groups transferred per hour per microgram of the enzyme (17). Experimentally, 
TbPRMT7 has been shown to catalyze the methyl transfer of bovine histones, myelin 
basic proteins, and several T. brucei RNA binding proteins (17).  While the exact 
function of this enzyme is still unknown, these findings suggest that TbPRMT7 may 
serve a function in several cellular processes (17).  
 
The Importance of Lipins in T. brucei  
The lipin family of proteins is important in the production of lipids. These 
proteins function as phosphatidate phosphatase enzymes that catalyze the 
dephosphorylation of phosphatidic acid to diaglycerol. Diaglycerol is a cell signaling 
molecule that aids in the synthesis of triaglycerol; an energy storage molecule that plays a 
key role in the maintenance of energy homeostasis (18).  Lipin-1 is the most recognized 
and studied of the lipin family of proteins. Mutations in this lipin have presented with 
insulin resistance, neonatal fatty liver, elevated triglyceride levels, and abnormal 
distribution of fats in mice (18). These lipin proteins have also been shown to be 
dependent on Mg2+ for proper enzymatic activity. Without it, binding sites on these lipins 
is inactive (18).  
Mammalian lipin has orthologs present in many different species, such as 
trypanosomes. The protein TbLpn was first uncovered during a yeast two hybridscreen of 
proteins interacting with TbPRMT1, the major protein arginine methyltransferase in T. 
brucei (14). TbLpn displays the conserved N-LIP and C-LIP domains that are present in 
all lipin proteins. These were the only two domains found on TbLpn and may be useful in 
finding a drug target against T. brucei in mammals (19). TbLpn mainly interacts with 
TbPRMT1 and is mainly localized in the cytosol.  In vivo, TbLpn displays phosphtidic 
acid phosphatase (PAP) activity. This enzymatic activity controls the balance of 
phosphatidic acid, diacyglycerol (20). This activity demonstrates, again, that TbLpn is a 
lipin that should be further studied in T. brucei elimination within a mammalian host.  
 
 
 
  
Materials and Methods 
 
Preparation of trypanosome cell extracts 
 
Procyclic form Trypanosoma brucei brucei 29-13 cells that have been engineered 
to allow disruption of TbPRMT7 by RNAi were grown in SM medium supplemented 
with 10% fetal bovine serum (FBS), 15 µg/ml G418, 50 µg/ml hygromycin B, and 2.5 
µg/ml phleomycin were incubated at 27 °C in the presence (induced) or absence 
(uninduced) of 2.5 µg/ml tetracycline for 2 days.  Cells were first centrifuged at 3,750 
RPM for 10 minutes at 4 °C in a accuSpin 3R centrifuge (Fisher Scientific). The cell 
pellet was washed twice in 25ml of Buffer A [150 mM sucrose, 20 mM KCl, 2 mM 
MgCl2, 20 mM Hepes (pH to 7.9)].  The final pellet was resuspended in 2 ml of buffer A 
to which NP-40 was added at a final concentration of 0.2%. Cells were lysed by three 
passages through a 26-gauge needle, being careful to avoid excess foaming.  
 
Phosphatidic Acid Phosphatase Assay 
 
A Phosphatidic Acid Phosphatase Assay is used to measure the activity of TbLpn 
when it is methylated by any of the five TbPRMT species that have been identified.  I 
studied TbPRMT7. As stated in the introduction, TbLpn has the ability to catalyze the 
dephosphorylation of phosphatidic acid to diaglycerol. Phosphate is a second product of 
this reaction and may be used to measure the effect of TbPRMT methylation on TbLpn 
on its ability to catalyze this process.  Ten separate samples were created under different 
conditions. 10 milliliters of a 10X Buffer was added to each tube. This buffer consisted of 
0.5 M Tris (pH 7.5), and 10 mM MgCl2.  The first and second samples contained 10 
microliters (µl) of buffer and 2 µl of 1,2-dioctanoyl-sn-glycero-3-phosphate (DiC8 PA), a 
cell permeable phosphatidic acid (5), and 88 µl of water. The third and fourth samples 
contained 10 µl of the 10X buffer, 2 µl of DiC8 PA, 78 µl of water, and 10 µl of cell 
extract of TbPRMT7-tet, i.e. cells that have not been induced for RNAi (contains wild 
type levels of TbPRMT7 enzyme).  Samples five and six were very similar to samples 3 
and 4. In samples five and six, cell extract TbPRMT7 +tet was used rather than cell 
extract TbPRMT7-tet. This means that RNA interference was induced, and the cells 
contain less TbPRMT7, and thus less TbLpn should be methylated in the cell sample. 
Samples seven and eight contained 10 µl of the 10X Buffer, 10 µl of cell extract 
TbPRMT7-tet, and 80 µl of water. The final set of samples, nine and ten, each contained 
10 µl of the 10X buffer, 10 µl of cell extract +tet, and 80 µl of water.   
These ten samples were incubated at 30 °C for 30 minutes. After this incubation 
period, 200 µl of ammonium molybdate-malachite green reagent (1 volume of 34 mM 
ammonium molybdate in 5M HCl + 3 volumes of 2.16 mM Malachite Green oxalate) 
was added to each of the tubes. This reagent allows the color of the sample to develop 
based on the amount of phosphate produced. If more phosphate is developed as a waste 
product, then the color will be darker. These samples were then mixed by inversion, and 
allowed to incubate for 30 minutes at room temperature.  After this period, 300 µl of 
water was added to each of the samples. The absorbance values were then measured at 
660 nm.  
 
  
 
Results 
 Through the analysis of a Phosphatidic Acid Phosphatase Assay, we were able to 
see a visual representation of TbLpn activity.   I studied the effect of down regulating the 
activity of TbPRMT7 on TbLpn activity. A sample of un-RNAi-induced TbPRMT7 was 
analyzed along with a sample of tet-induced TbPRMT7.  The goal of the tet-induced 
sample was to show the effects of down regulating the action of the TbPRMT7 enzyme 
on TbLpn. This experiment resulted in an uninduced sample with a phosphatase activity 
level of 17 nanomoles of Pi (phosphate) released per minute per milligram of protein. 
The tet-induced sample resulted in a phosphatase activity level of 12 nanomoles of Pi 
released per minute per milligram of protein, as shown in figure 6.  Another student 
working on this project analyzed the activity of uninduced TbPRMT1 versus tet-induced 
TbPRMT1 using the same method used in this project.  
  
Figure 6. This graph shows the effect of RNAi interference on TbPRMT7 activity 
Discussion 
 The main goal of this experiment was to understand how TbPRMT7 affects the 
activity of TbLpn. TbPRMT7 is an enzyme found naturally in T. brucei.  Unlike 
TbPRMT1, little is known about TbPRMT7 function in vivo.  We knew from previous 
experimentation that TbPRMT enzymes may aide in arginine methylation of 
TbLpn.  TbLpn is a lipin homologue that has been shown to undergo arginine 
methylation as a posttranscriptional modification.  It has been previously demonstrated 
that TbLpn is able to carry out the dephosphorylation of phosphatidic acid into 
diacylglycerol with the release of inorganic phosphate.  In order to address the effect of 
TbLpn methylation by TbPRMT7 on its enzymatic activity, we measured the release of 
inorganic phosphate from the substrate DiC8 PA using T. brucei cells expressing wild-
type levels of TbPRMT7, as well as cells whose TbPRMT7 expression has been down-
regulated by RNAi.    
The uninduced sample showed a slightly higher phosphatidic acid phosphatase 
activity compared to the tet-induced sample.  Our initial hypothesis was, “If TbPRMT7 
plays a significant role in the arginine methylation and enzymatic activity of TbLpn, then 
down-regulation of TbPRMT7 expression by tet-induced RNAi will result in a decrease 
in the amount of phosphatase activity compared to the uninduced cells.”  However, 
because of the calculated error that is shown in Figure 2, we cannot say for sure that 
methylation by TbPRMT7 plays a significant role in TbLpn phosphatidic acid 
phosphatase activity.  
As previously stated in this paper, TbPRMT7 is a type III TbPRMT.  This means 
that it only transfers only methyl carbon group onto the lipin before its activity ceases 
(17).  It is the only type III protein methyltransferase that has shown any significant 
activity in T. brucei in vivo (17).  TbPRMT1 has been shown to be important in AMDA 
formation in vivo, classifying it as a type I PRMT.  Recent studies have shown that 
TbPRMT1 interacts with TbLpn in vivo (17).  
In the future this enzyme, along with the other three TbPRMT enzymes that have known 
actions within this protozoan species, should be analyzed further.  Future research should 
work to understand exactly what the mechanism of action is for these enzymes. 
Researchers should also study whether these protein methyltransferases have any 
function in phospholipid bilayer synthesis.  It has been indicated that TbLpn is involved 
in the production of a phospholipid bilayer in T. brucei (17).  If any of these enzymes 
regulate phospholipid bilayer synthesis, they may aid in the production of the 
typanosomal cell membrane.  Many treatments for bacterial, and fungal pathogens target 
the cell wall or cell membrane to destroy the cell. If future research can prove that TbLpn 
is involved in the production of a phospholipid bilayer and VSG synthesis, then it, and 
the TbPRMT enzymes that regulate it, will be excellent candidates for a new method of 
treatment against African Trypanosomiasis.  
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